Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments

Schizophrenia Research

Volumn 159, Issue 2-3, 2014, Pages 376-384

  Zhang, Chen ^a,b   Fang, Yiru ^a   Xu, Lin ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

Antipsychotics; Glutamate receptor; Morris water maze; Synaptic plasticity

Indexed keywords

GLUTAMATE RECEPTOR 1; HALOPERIDOL; OLANZAPINE; SERINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; LEARNING DISORDER; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SCHIZOPHRENIA; SPATIAL LEARNING; SPATIAL MEMORY; UPREGULATION; WORKING MEMORY;

EID: 84922461418     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.054     Document Type: Article

References (51)

1. Adell A., Jimenez-Sanchez L., Lopez-Gil X., Romon T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?. Schizophr. Bull. 2012, 38(1):9-14.
2. Andersen R., Fagerlund B., Rasmussen H., Ebdrup B.H., Aggernaes B., Gade A., Oranje B., Glenthoj B. The influence of impaired processing speed on cognition in first-episode antipsychotic-naive schizophrenic patients. Eur. Psychiatry 2013, 28(6):332-339.
3. Bliss T.V., Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J. Physiol. 1973, 232(2):331-356.
4. Broome M.R., Fusar-Poli P., Matthiasson P., Woolley J.B., Valmaggia L., Johns L.C., Tabraham P., Bramon E., Williams S.C.R., Brammer M.J., Chitnis X., Zelaya F., McGuire P.K. Neural correlates of visuospatial working memory in the 'at-risk mental state'. Psychol. Med. 2010, 40(12):1987-1999.
5. Carrion R.E., Goldberg T.E., McLaughlin D., Auther A.M., Correll C.U., Cornblatt B.A. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am. J. Psychiatry 2011, 168(8):806-813.
6. Caruana D.A., Alexander G.M., Dudek S.M. New insights into the regulation of synaptic plasticity from an unexpected place: hippocampal area CA2. Learn. Mem. 2012, 19(9):391-400.
7. Chang W.C., Hui C.L., Tang J.Y., Wong G.H., Chan S.K., Lee E.H., Chen E.Y. Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study. Psychol. Med. 2013, 43(9):1-11.
8. Chen X.S., Zhang C., Xu Y.F., Zhang M.D., Lou F.Y., Chen C., Tang J. Neonatal ventral hippocampal lesion as a valid model of schizophrenia: evidence from sensory gating study. Chin. Med. J. (Engl.) 2012, 125(15):2752-2754.
9. Dias R.B., Ribeiro J.A., Sebastiao A.M. Enhancement of AMPA currents and GluR1 membrane expression through PKA-coupled adenosine A2A receptors. Hippocampus 2012, 22(2):276-291.
10. Ehlers M.D. Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron 2000, 28(2):511-525.
11. Eichenbaum H. A cortical-hippocampal system for declarative memory. Nat. Rev. Neurosci. 2000, 1(1):41-50.
12. Enomoto T., Ishibashi T., Tokuda K., Ishiyama T., Toma S., Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav. Brain Res. 2008, 186(2):197-207.
13. Ettinger U., Williams S.C.R., Fannon D., Premkumar P., Kuipers E., Moller H.J., Kumari V. Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology (Berl) 2011, 216(1):17-27.
14. Guo X., Zhai J., Wei Q., Twamley E.W., Jin H., Fang M., Hu M., Zhao J. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci. Lett. 2011, 503(2):141-146.
15. Hanlon F.M., Houck J.M., Pyeatt C.J., Lundy S.L., Euler M.J., Weisend M.P., Thoma R.J., Bustillo J.R., Miller G.A., Tesche C.D. Bilateral hippocampal dysfunction in schizophrenia. Neuroimage 2011, 58(4):1158-1168.
16. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004, 174(1):151-162.
17. Harvey P.D., Keefe R.S., Patterson T.L., Heaton R.K., Bowie C.R. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J. Clin. Exp. Neuropsychol. 2009, 31(4):462-471.
18. Henseler I., Falkai P., Gruber O. A systematic fMRI investigation of the brain systems subserving different working memory components in schizophrenia. Eur. J. Neurosci. 2009, 30(4):693-702.
19. Jibiki I., Wakita S., Kubota T., Kurokawa K., Fukushima T., Yamaguchi N. Haloperidol-induced blockade of induction of long-term potentiation in perforant path-dentate gyrus pathway in chronically prepared rabbits. Pharmacol. Biochem. Behav. 1993, 46(4):847-852.
20. Koolschijn P.C.M.P., van Haren N.E.M., Cahn W., Schnack H.G., Janssen J., Klumpers F., Hulshoff H.E., Kahn R.S. Hippocampal volume change in schizophrenia. J. Clin. Psychiatry 2010, 71(6):737-744.
21. Korchounov A., Ziemann U. Neuromodulatory neurotransmitters influence LTP-like plasticity in human cortex: a pharmaco-TMS study. Neuropsychopharmacology 2011, 36(9):1894-1902.
22. Krakowski M.I., Czobor P., Nolan K.A. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J. Clin. Psychopharmacol. 2008, 28(5):485-493.
23. Kucharska-Pietura K., Tylec A., Czernikiewicz A., Mortimer A. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med. Sci. Monit. 2012, 18(1):CR44-CR49.
24. Kuperberg G., Heckers S. Schizophrenia and cognitive function. Curr. Opin. Neurobiol. 2000, 10(2):205-210.
25. Lau C.G., Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 2007, 8(6):413-426.
26. Levin E.D., Bushnell P.J., Rezvani A.H. Attention-modulating effects of cognitive enhancers. Pharmacol. Biochem. Behav. 2011, 99(2):146-154.
27. Li H.B., Mao R.R., Zhang J.C., Yang Y., Cao J., Xu L. Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol. Psychiatry 2008, 64(4):286-292.
28. Lu W.H., Zhang C., Yi Z.H., Li Z.Z., Wu Z.G., Fang Y.R. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J. Mol. Neurosci. 2012, 47(3):505-510.
29. Manahan-Vaughan D., von Haebler D., Winter C., Juckel G., Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 2008, 18(2):125-134.
30. Matynia A., Kushner S.A., Silva A.J. Genetic approaches to molecular and cellular cognition: a focus on LTP and learning and memory. Annu. Rev. Genet. 2002, 36:687-720.
31. Mayer J.S., Park S. Working memory encoding and false memory in schizophrenia and bipolar disorder in a spatial delayed response task. J. Abnorm. Psychol. 2012, 121(3):784-794.
32. Mayford M., Siegelbaum S.A., Kandel E.R. Synapses and memory storage. Cold Spring Harb. Perspect. Biol. 2012, 4(6):a005751.
33. Mutlu O., Ulak G., Celikyurt I.K., Akar F.Y., Erden F. Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol. Biochem. Behav. 2011, 98(3):398-404.
34. Oh M.C., Derkach V.A., Guire E.S., Soderling T.R. Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation. J. Biol. Chem. 2006, 281(2):752-758.
35. Park S.W., Phuong V.T., Lee C.H., Lee J.G., Seo M.K., Cho H.Y., Fang Z.H., Lee B.J., Kim Y.H. Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci. Res. 2011, 71(4):335-340.
36. Ploeger G.E., Spruijt B.M., Cools A.R. Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol. Behav. Neurosci. 1994, 108(5):927-934.
37. Sanderson D.J., Good M.A., Seeburg P.H., Sprengel R., Rawlins J.N., Bannerman D.M. The role of the GluR-A (GluR1) AMPA receptor subunit in learning and memory. Prog. Brain Res. 2008, 169:159-178.
38. Scoville W.B., Milner B. Loss of recent memory after bilateral hippocampal lesions. J. Neuropsychiatry Clin. Neurosci. 2000, 12(1):103-113.
39. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berl) 1996, 124(1-2):126-133.
40. Smith R.C., Infante M., Singh A., Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int. J. Neuropsychopharmacol. 2001, 4(3):239-250.
41. Stip E., Remington G.J., Dursun S.M., Reiss J.P., Rotstein E., MacEwan G.W., Chokka P.R., Jones B., Dickson R.A. A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. J. Clin. Psychopharmacol. 2003, 23(4):400-404.
42. Vales K., Bubenikova-Valesova V., Klement D., Stuchlik A. Analysis of sensitivity to MK-801 treatment in a novel active allothetic place avoidance task and in the working memory version of the Morris water maze reveals differences between Long-Evans and Wistar rats. Neurosci. Res. 2006, 55(4):383-388.
43. Wood S.J., Proffitt T., Mahony K., Smith D.J., Buchanan J.A., Brewer W., Stuart G.W., Velakoulis D., McGorry P.D., Pantelis C. Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology?. Psychol. Med. 2002, 32(3):429-438.
44. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8(3):457-472.
45. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res. 2007, 89(1-3):211-224.
46. Yang Y., Xiong G.J., Yu D.F., Cao J., Wang L.P., Xu L., Mao R.R. Acute low-dose melamine affects hippocampal synaptic plasticity and behavior in rats. Toxicol. Lett. 2012, 214(1):63-68.
47. Zhang C., Li M. Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav. Pharmacol. 2012, 23(1):66-79.
48. Zhang C., Fang Y., Li M. Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence. Pharmacol. Biochem. Behav. 2011, 98(1):155-160.
49. Zhang C., Li Z.Z., Shao Y., Xie B., Du Y.S., Fang Y.R., Yu S.Y. Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. J. Mol. Neurosci. 2011, 43(3):406-411.
50. Zhang Q.M., Shen Q.G., Xu Z.S., Chen M., Cheng L.N., Zhai J.G., Gu H., Bao X., Chen X.Y., Wang K.Q., Deng X.X., Ji F., Liu C.X., Li J., Dong Q., Chen C.S. The effects of CACNA1C gene polymorphism on spatial working memory in both healthy controls and patients with schizophrenia or bipolar disorder. Neuropsychopharmacology 2012, 37(3):677-684.
51. Zhang C., Cai J., Zhang J., Li Z., Guo Z., Zhang X., Lu W., Zhang Y., Yuan A., Yu S., Fang Y. Genetic modulation of working memory deficits by ankyrin 3 gene in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 50:110-115.